3D InSight™ Cancer Drug Efficacy Testing Service | InSphero

Biochemical and phenotypic assessment of drug potency and efficacy

Test your compounds or biologics of interest to assess their potency (EC50) and efficacy (maximum response) on tumor microtissues using 3D-optimized biochemical (ATP) and phenotypic (size) endpoints.

Service Protocol

  • Choose a 3D InSight™ Tumor model and supply at least 2 test compounds
  • Choose controls (e.g., Staurosporine, MEK162, Ipatasertib, Sorafenib/Sunitinib, DMSO, etc.)
  • Produce 9-point dose-response in quadruplicate
  • Perform 11-day efficacy testing assay with dosing at day 0, 4, and 7

Characterization Data

Slide Evaluate anti-tumor efficacy in physiologically relevant 3D models. Receive ATP-based dose-response curve and dose-dependent size-based growth kinetics. Slide Leverage non-disruptive, continuous size assessment to monitor tumor response over time, preserving samples for optional customized endpoints. Potency and efficacy of the MEK inhibitor Binimetinib (MEK-162) in HepG2 spheroids.

Service at a Glance

Download our brochure for details on the standard protocol.

Service Report includes

  • ATP-based dose-response curve at day 11
  • Size-based dose-response curve and growth kinetics over time
  • Efficacy (IC50) values
Catalog # Description
SP-01-041-02 3D InSight™ Efficacy Testing Service
(2 or more compounds, 2 controls, 1 model)

Request Additional Resources

Brochure: Oncology Services


Poster: 3D InSight™ Oncology Drug Discovery Platform


Brochure: Immuno-Oncology Services


Find out how you can screen new cancer drugs more efficiently

with services using our advanced 3D tumor models.

Get Started